- $58.75m
- $37.87m
- $48.47m
Gossamer Bio's Q3 net loss widens to $48.2 mln
Brief: Gossamer Bio Q3 EPS USD -0.21
Brief: Respira Therapeutics Says Enters Into Agreement Granting Gossamer Option To Acquire Co From Samsara Biocapital
Brief: Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Gossamer Bio Q2 EPS USD -0.17
Brief: Gossamer Bio Announces Completion Of Enrollment In Registrational Phase 3 PROSERA Study For The Treatment Of PAH
Brief: Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule
Gossamer Bio Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Gossamer Bio Q1 EPS USD -0.16
Gossamer Bio Inc expected to post a loss of 19 cents a share - Earnings Preview
Gossamer Bio Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: Gossamer Bio Announces Inducement Grant Under
Gossamer Bio Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Gossamer Bio Q4 EPS USD -0.15
Brief: Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Gossamer Bio Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Cautious uptake of Merck's Winrevair gives opportunity to rivals, Oppenheimer says